The identification, careful characterisation, and follow-up of cohorts of patients with HRAS/BRAF mutation positive tumours could enable the natural history of such tumours (e.g., absence of malignant or recurrent disease) and so facilitate personalised management of patients with these tumours. The gene discussed is HRAS; the disease is neoplasm.